Purpose Of Review: In this review, we outline the usage and formulations of gonadotropin-releasing hormone analogs (GnRHas) in central precocious puberty (CPP), short stature, and gender diverse individuals, as well as adverse effects, long-term outcomes, and monitoring of therapy. There is a particular focus on citing references published within the last 24 months.
Recent Findings: Long-acting formulations of GnRHa now include Federal Drug Administration approval for subcutaneous injections. Significant adverse events continue to be rarely reported; extremely rare events include arterial hypertension and pseudotumor cerebri. There continue to be no significant long-term consequences including the impact upon body mass index and bone mineral density, which appear to be transient. GnRHas have been used in differences of sexual development (DSD) and increasingly in the treatment of adolescent transgender individuals.
Summary: GnRHas remain as the only fully efficacious therapy for CPP and effectively suppress pubertal hormones in other situations. The use of GnRHa therapy in gender incongruent individuals has proven beneficial and has become a standard of care, whereas use in those with DSDs should still be considered experimental.
Video Abstract: http://links.lww.com/MOP/A62.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOP.0000000000001026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Childhood obesity and central precocious puberty.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Second Ward of Endocrinology Department, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000.
Central precocious puberty (CPP) is an endocrine disorder in children caused by the early activation of the hypothalamic-pituitary-gonadal axis (HPGA), leading to elevated gonadotropin-releasing hormone (GnRH), which triggers the development of gonads and the secretion of sex hormones. This eventually results in the development of internal and external genitalia and secondary sexual characteristics. CPP significantly affects the physical and mental health of children and may increase the risk of various adult diseases.
View Article and Find Full Text PDFBasal and stimulated inhibin B in pubertal disorders.
J Clin Endocrinol Metab
January 2025
3Department of Metabolism, Digestion and Reproduction, Imperial College London.
Pubertal disorders in the form of delayed puberty (DP) or precocious puberty (PP) can cause considerable anxiety to both children and parents. Since the clinical and biochemical signatures of self-limiting and permanent conditions overlap considerably, it can be hard to determine whether to offer them reassurance or intervention. Researchers have thus long been searching for a robust test to indicate that the process of endogenous puberty is underway and is likely to proceed to completion.
View Article and Find Full Text PDFGonadotropin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
Cochrane Database Syst Rev
January 2025
Institute of Education in Healthcare and Medical Sciences, University of Aberdeen, Aberdeen, UK.
Background: Gonadotropin-releasing hormone agonists (GnRHa) are commonly used in assisted reproduction technology (ART) cycles to prevent a luteinising hormone (LH) surge during controlled ovarian hyperstimulation (COH) prior to planned oocyte retrieval, thus optimising the chances of live birth. We compared the benefits and risks of the different GnRHa protocols used.
Objectives: To evaluate the effectiveness and safety of different GnRHa protocols used as adjuncts to COH in women undergoing ART.
The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study.
F S Rep
December 2024
Department of Embryology, Newlife Fertility Centre, Mississauga, Ontario, Canada.
Objective: To compare in vitro fertilization treatment outcomes for the oral gonadotropin-releasing hormone (GnRH) antagonist elagolix (E) to the conventionally used injectable GnRH antagonist ganirelix (G) for achieving pituitary gonadotropin suppression during a controlled ovarian stimulation (COS) cycle.
Design: Retrospective cohort study.
Setting: Private university-affiliated fertility center.
Optimising Luteinising Hormone Levels on Trigger Day for Improved Ovarian Response and Pregnancy Outcomes in Gonadotropin-Releasing Hormone Antagonist Protocols: A Retrospective Cohort Study.
BJOG
January 2025
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Objective: To determine the optimal luteinising hormone (LH) level on the trigger day and its impact on pregnancy outcomes in gonadotropin-releasing hormone (GnRH) antagonist protocols using a data-driven approach.
Design: Retrospective cohort study.
Setting: Third Affiliated Hospital of Guangzhou Medical University.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!